Achieve Life Sciences, Inc. (NASDAQ:ACHV) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Achieve Life Sciences, Inc., a late-stage ...

Achieve Life Sciences, Inc. (ACHV) has done well to advance its main clinical program, which would be the use of its drug cytisinicline for smoking cessation. The company has had an extensive program, ...

Achieve Life Sciences, Inc. beats earnings expectations. Reported EPS is $-0.36981, expectations were $-0.37. Operator: Greetings. Welcome to Achieve Life Sciences First Quarter 2025 Earnings ...

Achieve Life Sciences Inc. (NASDAQ:ACHV) is one of the Canadian penny stocks to buy right now. Lake Street’s Thomas Flaten maintained a Buy rating on Achieve Life Sciences Inc. (NASDAQ:ACHV) at $11.00 ...

Achieve Life Sciences, Inc. has submitted a New Drug Application (NDA) to the U.S. FDA for cytisinicline, which, if approved, would be the first new pharmacotherapy for nicotine dependence in 20 years ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

Invesco Ltd. lifted its stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV – Free Report) by 338.7% during the 1st quarter, HoldingsChannel reports. The firm owned 73,644 shares of the ...

Greetings. Welcome to Achieve Life Sciences’ First Quarter 2024 Earnings Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will ...